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Th e majority of ischemic strokes are due to car-
dioembolism (CE), large vessel atherothromboembo-
lism, small vessel occlusive disease, or other unusual 
mechanisms. However, many ischemic strokes occur 
without a well-deﬁ ned etiology and are labeled as 
cryptogenic. Other terms used in the literature to de-
scribe cryptogenic stroke (CS) include cryptogenous 
stroke and infarcts of unknown, uncertain, or unde-
termined cause (IUC). CS accounts for 30 to 40 per-
cent of ischemic strokes in most modern stroke regis-
tries and databases.
By the TOAST classiﬁ cation, which is the most 
commonly used in clinical practice, CS (or stroke of un-
determined origin in TOAST terminology) is deﬁ ned 
as brain infarction that is not attributable to a source 
of deﬁ nite cardioembolism (CE), large artery athero-
sclerosis (LAA), or small artery disease (SAD) despite 
extensive vascular, cardiac, and serologic evaluation.
In the past, about 40% of ischaemic strokes were 
judged to be cryptogenic, but with technical and med-
ical advances this proportion has been as low as 18%. 
Study by Rolfs and colleagues’ found out that  4% of 
patients with cryptogenic stroke had Fabry’s disease. 
Th e investigators predict that this value might cor-
respond to a prevalence of about 1·2% in the general 
stroke population aged 18–55 years.
Fabry disease is an X-linked inborn error of gly-
cosphingolipid catabolism resulting from deﬁ ciency 
of the lysosomal hydroxylase, alpha galactosidase A 
(AGLA). In humans, the disease is characterised by 
the systemic accumulation of the glycosphingolipid 
substrate, ceramide trihexoside (CTH) and ceramide 
dihexoside in tissue. Clinical manifestations of Fabry 
disease include chronic pain, kidney impairment, skin 
lesions, ocular opacities, vascular deterioration, stroke 
and cardiac deﬁ ciencies leading to premature mortal-
ity. Recently, enzyme replacement therapy (ERT) has 
become available.
Enzyme replacement therapy has given new hope 
to patients with Fabry’s disease. Agalasidase is recom-
binant form of the human enzyme a -Gal A, which 
is deﬁ cient in patients with Fabry disease. Data from 
clinical trials show a decrease in GL-3 levels following 
enzyme replacement, reversal in lipid tissue storage, 
stabilized or improved renal and cardiac function, and 
reduction or relief of neuropathic pain.
